Injectable Anesthesia for Mice: Combined Effects of Dexmedetomidine, Tiletamine-Zolazepam, and Butorphanol

Abstract

Anesthetic protocols for murine models are varied within the literature and medetomidine has been implicated in the development of urethral plugs in male mice. Our objective was to evaluate the combination of butorphanol, dexmedetomidine, and tiletamine-zolazepam. A secondary objective was to identify which class of agent was associated with urethral obstructions in male mice. BALB/c male (n = 13) and female (n = 23) mice were assigned to dexmedetomidine and tiletamine-zolazepam with or without butorphanol or to single agent dexmedetomidine or tiletamine-zolazepam. Anesthesia was achieved in 58% (14/24) of mice without butorphanol and in 100% (24/24) of mice with butorphanol. The combination of dexmedetomidine (0.2 mg/kg), tiletamine-zolazepam (40 mg/kg), and butorphanol (3 mg/kg) resulted in an induction and anesthetic duration of 12 and 143 minutes, respectively. Urethral obstructions occurred in 66% (25/38) of trials in male mice that received dexmedetomidine with a mortality rate of 38% (5/13). Tiletamine-zolazepam, when used alone, resulted in a 0% (0/21) incidence of urethral obstructions. Combination use of dexmedetomidine, tiletamine-zolazepam, and butorphanol results in a longer and more reliable duration of anesthesia than the use of dexmedetomidine and tiletamine-zolazepam alone. Dexmedetomidine is not recommended for use in nonterminal procedures in male mice due to the high incidence of urethral obstructions and resultant high mortality rate.

The hydroxypropyl‐β‐cyclodextrin‐minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia

“…The general anesthesia was induced by intramuscular injections of Zoletil 50/50 (Pfizer) ip using three refracted doses of 20 mg/kg for a cumulative dose of 60 mg/kg. This drug induced a rapid and general anesthetic effect and complete muscle relaxation with no arrhythmias, avoiding the risk of epilepsy, and did not cause hepatic and/or renal toxicity in our experiments 42. Moreover, awakening was rapid, without spastic movements, and therefore without the risk of wounding the animals.…”

“…This corresponded to 35 mg (77.7 mg/kg/day) over 5 days of treatment and 70 mg (155.5 mg/kg/day) after an additional 5 days of treatment. Animal preparation was performed as described below; briefly, the dorsal area of the rats was shaved using an appropriate cream under moderate anaesthesia 41,42. Starting 7 days after the surgical implantation of the telemeter in the rat abdominal cavity, BP and ECG measurements were collected continuously over a period of 8 days under baseline conditions (internal control conditions) in freely moving animals.…”

Bridging repair of the abdominal wall in a rat experimental model. Comparison between uncoated and polyethylene oxide-coated equine pericardium meshes

“…The isoflurane maintained general anaesthesia during ultrasound examination, at a level of 1.5-2%. The combination of these drugs induced a rapid anaesthetic action, complete muscle relaxation, without arrhythmias, epilepsy, hepatic/renal toxicity, nor spastic movements during awakening 49 . Analgesic (buprenorphine, 15 ± 3 µg) and antibiotic (enrofloxacin, 10 mg) single doses were administered by subcutaneous or intramuscular injection.…”

“…Analgesic (buprenorphine, 15 ± 3 µg) and antibiotic (enrofloxacin, 10 mg) single doses were administered by subcutaneous or intramuscular injection. Anaesthetised rats were shaved on the surgical site, placed on a heated surgical pad in dorsal recumbence, disinfected with povidone-iodine and draped with sterile gauze 49 .…”

Dexmedetomidine reduces inflammation in traumatic brain injury by regulating the inflammatory responses of macrophages and splenocytes

“…Dexmedetomidine (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was used at a concentration of 20 µg/kg and was employed to treat mice immediately following trauma induction and was administered through and intravenous (i.v.) tail injection for a single administration (25,(31)(32)(33). Yohimbine (YOH) was selected as the α-2-adrenergic receptor antagonist (1 mg/kg; Sigma-Aldrich; Merck KGaA).…”